Tiziana Life Sciences, a biotechnology company specializing in immunomodulation therapies, has filed for Orphan Drug Designation for intranasal foralumab in the treatment of non-active secondary progressive multiple sclerosis (na-SPMS). This groundbreaking therapy has demonstrated effectiveness in clinical and non-clinical evidence, supported by studies conducted at the Brigham & Women’s Hospital in Boston, Massachusetts.
Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis:Tiziana Life Sciences recently announced the dosing of the first patient in its Phase 2a study to compare two doses of intranasal foralumab with a placebo in na-SPMS patients. This double-blind, placebo-controlled trial involves six investigational centers and up to 18 patients per treatment arm. The primary endpoint of the trial focuses on evaluating the change in microglial activation through PET scans. Besides clinical evaluations, novel immuno-biomarkers will be examined for their predictive relevance. Central review of PET scans and images plays a crucial role in this comprehensive study.
Expanded Access Program for Multiple Sclerosis:Tiziana Life Sciences also reported that it enrolled and dosed four new patients with na-SPMS in the Expanded Access (EA) Program, conducted in collaboration with the Brigham and Women’s Hospital. Including these participants, a total of ten patients are now being actively followed in this program.
Impact on Tiziana Life Sciences:Tiziana’s FDA request for Orphan Drug Designation for intranasal foralumab signifies a significant milestone for both the company and patients suffering from na-SPMS. If approved, this therapy would be the first-ever designated treatment for na-SPMS, highlighting Tiziana’s pioneering position in breakthrough immunomodulation therapies. With ongoing Phase 2a trials and an expanding participant pool through the EA Program, Tiziana is demonstrating its commitment to advancing research in multiple sclerosis treatment and improving patients’ quality of life.
Conclusion:Tiziana Life Sciences’ recent steps towards developing intranasal foralumab as a potential treatment for na-SPMS highlight the company’s dedication to innovative drug delivery methods and effective immunomodulation therapies. The outcomes of the Phase 2a trial and the expansion of the EA Program will provide valuable insights into the therapeutic potential of foralumab. These advancements offer hope for the numerous individuals affected by na-SPMS, potentially heralding a new era of treatment for this currently unmet medical need.
Comments